Calcium Channel Blockers
To view the entire topic, please log in or purchase a subscription.
Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:
-- The first section of this topic is shown below --
INDICATIONS
FDA
- Hypertension
- See Table Table 1. for calcium channel blocker - specific indications
FDA Indication(s) | Pharmacokinetics | Pregnancy and Breastfeeding Risk[10] | Cost and Formulation | |
DIHYDROPYRIDINE | ||||
Amlodipine | Treatment of HTN; treatment of coronary artery disease (including chronic stable angina and vasospastic angina) | A: ~ 64% - 90% oral[8] | Pregnancy: limited human data - animal data suggest moderate risk Breastfeeding: limited human data - probably compatible; present in breast milk | Generic available[9] |
Nifedipine (extended-release) | Treatment of HTN; treatment of chronic stable or vasospastic angina | A:90% | Category C Pregnancy: human data suggest low risk Breasfeeding: limited human data - probably compatible; enters breast milk (AAP considers compatible) | Generic available extended-release[9] |
Felodipine | Treatment of HTN | A: 100% | Category C Pregnancy: limited human data - animal data suggest risk Breasfeeding: no human data - probably compatible; excretion in breast milk should be expected due to low molecular weight | Generic available[9] |
NON-DIHYDROPYRIDINE | ||||
Verapamil | Treatment of HTN, angina, atrial fibrillation (rate control), treatment and prophylaxis of supraventricular tachycardia | A: 90% | Category C Pregnancy: compatible Breastfeeding: limited human data - probably compatible; enters breast milk | Generic available
|
Diltiazem | Treatment of HTN, chronic stable angina or angina from coronary spasm | A: ~93% - 95% | Category C Pregnancy: human data suggest low risk Breastfeeding: limited human data - probably compatible; enters breast milk | Generic available extended release[9] 120mg(30 cap): $38.96 360mg(30 cap): $341.86 |
A = absorption; M = metabolism; E = excretion; AAP = American Academy of Pediatrics |
NON-FDA APPROVED USES
- Diabetic nephropathy (amlodipine, diltiazem)
- Hypertension - pregnancy (nifedipine)
-- To view the remaining sections of this topic, please log in or purchase a subscription --
INDICATIONS
FDA
- Hypertension
- See Table Table 1. for calcium channel blocker - specific indications
FDA Indication(s) | Pharmacokinetics | Pregnancy and Breastfeeding Risk[10] | Cost and Formulation | |
DIHYDROPYRIDINE | ||||
Amlodipine | Treatment of HTN; treatment of coronary artery disease (including chronic stable angina and vasospastic angina) | A: ~ 64% - 90% oral[8] | Pregnancy: limited human data - animal data suggest moderate risk Breastfeeding: limited human data - probably compatible; present in breast milk | Generic available[9] |
Nifedipine (extended-release) | Treatment of HTN; treatment of chronic stable or vasospastic angina | A:90% | Category C Pregnancy: human data suggest low risk Breasfeeding: limited human data - probably compatible; enters breast milk (AAP considers compatible) | Generic available extended-release[9] |
Felodipine | Treatment of HTN | A: 100% | Category C Pregnancy: limited human data - animal data suggest risk Breasfeeding: no human data - probably compatible; excretion in breast milk should be expected due to low molecular weight | Generic available[9] |
NON-DIHYDROPYRIDINE | ||||
Verapamil | Treatment of HTN, angina, atrial fibrillation (rate control), treatment and prophylaxis of supraventricular tachycardia | A: 90% | Category C Pregnancy: compatible Breastfeeding: limited human data - probably compatible; enters breast milk | Generic available
|
Diltiazem | Treatment of HTN, chronic stable angina or angina from coronary spasm | A: ~93% - 95% | Category C Pregnancy: human data suggest low risk Breastfeeding: limited human data - probably compatible; enters breast milk | Generic available extended release[9] 120mg(30 cap): $38.96 360mg(30 cap): $341.86 |
A = absorption; M = metabolism; E = excretion; AAP = American Academy of Pediatrics |
NON-FDA APPROVED USES
- Diabetic nephropathy (amlodipine, diltiazem)
- Hypertension - pregnancy (nifedipine)
There's more to see -- the rest of this topic is available only to subscribers.